Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Second PP Any news?
View:
Post by Infinity on Oct 28, 2022 3:38am

Second PP Any news?

TLT has huge potential, no question.  However this management which recognised  the potential and signged all the patents are not acting in good faith to the long time share holders of the company.  Barely disclosing any progress.  Multiple changes in the CEO and key management that are simply inexplicable.   Holding back news on the progress in the clinical research and discussion with regulators is not in the best interest of the share holders who have invested in this company for several years.  The management decided to DUMP the relationship UHN and PMH  the most recognised cancer treatment centers with no explanation.  Decided to move Li ka shing and St. Michael again with no explaination of the benefits of such a move.  Decided to cut off the relationship with some of the most recognised Doctors on the Medical Advisory Board like Dr. Jewet with no reason to the share holders.  This company lacks at the least communication skills.
Comment by StevenBirch on Oct 28, 2022 7:56am
I agree, the least the company can do is give you a personal update on a weekly basis, anything else is just plain negligence on their part.
Comment by ScienceFirst on Oct 28, 2022 9:47am
I guess Infinity subtly missed this one: Theralase launches Anti-Cancer Therapy Research Centre Toronto, Ontario – March 29, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug ...more  
Comment by jewel9m on Oct 28, 2022 9:59am
Great post ScienceFirst!!! Nice to refresh our short memories. It is easy for the share price fluctuations to make us forget about all the great things that have been accomplished.
Comment by langosta on Oct 28, 2022 12:49pm
There is a ton of them out there, just picked three. 6 years ago  https://youtu.be/G4zhWfftTsI 7 Years ago. https://youtu.be/l9rNgO9j-Yc https://youtu.be/bY5Ti9SAkeo 12 years ago
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250